Heat Biologics Shares Financial Report for Q1 2017

Heat Biologics (NASDAQ:HTBX) released a business and clinical update as they released their financials for the first quarter of 2017.
As quoted in the press release:

During the first quarter, Heat announced a number of major developments. First, it met the safety and efficacy endpoints in its Phase 1b lung cancer trial evaluating HS-110 in combination with Bristol-Myers Squibb’s anti-PD-1 checkpoint inhibitor, nivolumab (Opdivo®), enabling it to progress to Phase 2 clinical trials. Preliminary data suggests Heat’s therapeutic vaccine has the potential to significantly expand the percentage of patients responding to checkpoint inhibitors by increasing T cell activity within the tumor, thereby converting “cold” tumors into “hot” tumors.
“We are encouraged by these results, showing signs of synergistic efficacy with nivolumab,” said Jeff Wolf, Heat’s founder and CEO. “Patients with increased levels of tumor infiltrating lymphocytes (TIL) at 10 weeks saw a durable benefit, with 75% (6 out of 8 of these patients) alive at the one-year follow-up point. Additionally, 60% of the patients (3 of the 5 patients) exhibiting low TIL experienced significant tumor reduction, which compares favorably to the 10% response rate of low TIL patients reported for existing data on nivolumab alone.”
Researchers reported a strong correlation between T cell activation, tumor reductions and increased overall survival in the 12 of the 15 patients that were evaluable for ELISPOT analysis. Importantly, the timing of immune responses to HS-110 corresponded to the timing of observed clinical responses, and those responses appear to be sustained.

Click here to read the full press release.

Source: www.accesswire.com